GenSight Biologics Reports Full Year 2016 Financial Results

GenSight Biologics Completes Enrollment of REVERSE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy

GenSight Biologics receives FDA Orphan Drug Designation for GS030 in Retinitis Pigmentosa

GenSight Biologics reports sustained visual acuity gain at 78 weeks in its Phase I/II Study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)

GenSight Biologics reports its cash position as of September 30, 2016

GenSight Biologics receives approval to include teenage patients in RESCUE and REVERSE Phase III trials with GS010 in Leber’s Hereditary Optic Neuropathy

GenSight Biologics receives Orphan Drug Designation and Advanced Therapy Medicinal Product classification in Europe for GS030 in Retinitis Pigmentosa

GenSight Biologics confirms the success of its IPO by exercising 88.9% of the over-allotment option

GenSight Biologics announces the implementation of a liquidity contract with Oddo & Cie

GenSight Biologics announces successful IPO on Euronext Paris